AVGO vs MBX Stock Comparison
MBX currently leads AVGO in this stock comparison, with AIQ scores of 68 vs 52. The clearest difference is momentum.
What is the main difference between AVGO and MBX?
MBX leads the current stock comparison as MBX Biosciences, Inc. Common Stock, with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Broadcom Inc. vs MBX Biosciences, Inc. Common Stock
MBX leads
MBX leads by 16 AIQ points, primarily on Momentum and Quality, and the lead has widened from 13 points over 30 sessions.
Stable: 3 of 5 evidence groups support MBX, its lead is widening, and its signal state is cleanly positive.
Broadcom Inc.
MBX Biosciences, Inc. Common Stock
The Algovestiq AIQ Score currently favors MBX over AVGO, 68 versus 52 as of Nov 15, 2026. MBX's advantage is driven primarily by stronger momentum and quality. MBX also shows the weaker technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor MBX today, and the comparison is rated Stable on stability: analyst targets on the leader are widely dispersed. MBX lead: Strengthening — the AIQ differential moved from 13 to 16 points over 30 sessions.
Compare Broadcom Inc. and MBX Biosciences, Inc. Common Stock across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare AVGO and MBX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum40 vs 71MBX +31
- Quality69 vs 74MBX +5
- Risk Resilience47 vs 50Even
3 of 5 evidence groups favor MBX. MBX’s edge is concentrated in momentum and quality.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum -2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 6 active signals are unchanged.
Largest factor move: Momentum +3
New signals
- Accumulation Pattern — bullish, volume, medium horizon (1.59x)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
MBX's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — AVGO and MBX both carry a full feed there.
The central trade-off
MBX (MBX Biosciences, Inc. Common Stock): the stronger current systematic profile, led by momentum and quality.
AVGO (Broadcom Inc.): the counter-case, on fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
MBXMBX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
AVGOAVGO on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
MBXMBX on the Momentum factor, by 31 points.
Lower downside
MBXMBX carries the lower 1-month annualized volatility.
Analyst upside
MBXMBX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | AVGO | MBX | Note |
|---|---|---|---|
| Implied upside to target | +48.5% | +90.7% | MBX has more room |
| Target dispersion | +48.5% | +61.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 51 | 12 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor MBX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | MBX | 52 vs 68 |
| Fundamentals | AVGO | EPS growth 40.3% vs -65.4%; TTM ROE 13.1% vs -13.2% |
| Valuation | Not covered | Not covered |
| Technicals | MBX | Price vs 50-day 0.5% vs 0.3%; vs 200-day -5.6% vs 20.8% |
| Risk Resilience | Even | Risk Resilience 47 vs 50 |
| Analyst expectations | MBX | Target upside 48.5% vs 90.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVGO and MBX and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 16 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MBX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13MBX lead: Strengthening — the AIQ differential moved from 13 to 16 points over 30 sessions.
- Today
- MBX +16
- 52 vs 68
- 7 sessions ago
- MBX +17
- 50 vs 67
- 30 sessions ago
- MBX +13
- 55 vs 68
- 90 sessions ago
- MBX +16
- 59 vs 75
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 2 neutral, conflicted
Only AVGO
- Death Cross Active — bearish, trend, long horizon (6.38%)
- Beta Spike Warning — bearish, risk_regime, long horizon
7 bullish / 0 bearish / 2 neutral
Only MBX
- Golden Cross Active — bullish, trend, long horizon (20.41%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- TSI Bullish Crossover — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 4 more signals that do not separate them: ADX Trend Weakening, ATR Expansion - Breakout Mode, Accumulation Pattern, MACD Histogram Expanding Bullish.
AVGO is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -4.76%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +2.62%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1AVGO closes the Momentum gap — currently 31 points behind, the largest single contributor to MBX's edge.
- 2AVGO's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
AVGO leads on balance| Metric | AVGO | MBX |
|---|---|---|
| Revenue growth (YoY) | 33.4% | 0% |
| EPS growth (YoY) | 40.3% | -65.4% |
| Gross margin | 68.8% | 0% |
| Operating margin | 48.4% | 0% |
| Return on equity (TTM) | 13.1% | -13.2% |
| Debt to equity | 0.6 | 0.01 |
Performance
MBX leads 4 of 6 windows| Metric | AVGO | MBX |
|---|---|---|
| 1 week (5 sessions) | 18.2% | 8.9% |
| 1 month (20 sessions) | 5.6% | 12.8% |
| 3 months (63 sessions) | -11.6% | -18% |
| 6 months (126 sessions) | -18.4% | 72.4% |
| Year to date | 0.3% | 77.4% |
| 1 year (252 sessions) | -2.3% | 127.4% |
Technicals
MBX has the stronger structure| Metric | AVGO | MBX |
|---|---|---|
| RSI (14) | 53.2 | 53.3 |
| ADX (14) | 23 | 13.7 |
| Price vs 50-day | 0.5% | 0.3% |
| Price vs 200-day | -5.6% | 20.8% |
| Volatility (1M, annualized) | 70% | 68.2% |
Risk
Split| Metric | AVGO | MBX |
|---|---|---|
| Beta | 2.21 | 1.26 |
| Sharpe ratio | 0.21 | 1.42 |
| Sortino ratio | 0.29 | 2.43 |
| Max drawdown | -39.5% | -37.6% |
| Current drawdown | -27.9% | -20.9% |
| Annualized volatility | 48.6% | 77.3% |
| Value at risk (95%) | -4.6% | -7.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AVGO or MBX?
On the Algovestiq AIQ Score, MBX is the stronger of the two as of Nov 15, 2026, scoring 68 against AVGO's 52. The edge comes from momentum and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AVGO or MBX the better buy right now?
MBX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 3 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor MBX over AVGO?
The composite weights Quality, Value, Momentum and Risk Resilience. MBX leads Momentum by 31 points; MBX leads Quality by 5 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AVGO or MBX?
Analyst price targets imply +48.5% upside for AVGO and +90.7% for MBX, so the Street currently favors MBX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AVGO or MBX?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AVGO or MBX?
AVGO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AVGO or MBX?
MBX on the Momentum factor, by 31 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AVGO or MBX?
MBX is the more resilient of the two, so the other name carries the higher downside risk. MBX carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AVGO more profitable than MBX?
AVGO leads on the comparable margin measures — gross margin 68.8% vs 0%; operating margin 48.4% vs 0%; ttm roe 13.1% vs -13.2%.
Is MBX's lead over AVGO getting stronger or weaker?
MBX lead: Strengthening — the AIQ differential moved from 13 to 16 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the AVGO vs MBX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AVGO closes the Momentum gap — currently 31 points behind, the largest single contributor to MBX's edge; AVGO's Death Cross Active resolves — a bearish trend rule currently active against it; MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about AVGO and MBX?
AVGO: 2 bullish / 2 bearish / 2 neutral, conflicted. MBX: 7 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVGO is Death Cross Active (bearish, long horizon). On MBX it is Golden Cross Active (bullish, long horizon).
Compare AVGO and MBX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.